

## Round table: The Road to successful interventions

Live from the studio: Patient Information Session

Friday 9 July  
18:00 - 19:00

**Location** Virtual room 2

**Chairs** H. Van Poppel, Leuven (BE)  
E. Rogers, Renmore, Galway (IE)

This round table discussion has been funded by Ferring Pharmaceuticals. The programme of this online activity has been independently developed and approved by the EAU Patient Office.

### Learning objectives

The objective of the Roundtable is to discuss the shared responsibilities of both the healthcare provider and patient during a patient's care pathway. Do healthcare providers ask the right questions during intake? Do patients provide all the information the healthcare provider needs, such as a detailed medical history and anything that could be relevant to the decision-making process, as to what care pathway to take?

18:00 - 18:02

**Welcome and introduction**

18:02 - 18:16

**Awareness, education and communication**

18:02 - 18:04

**What did you know about PCa?**

To be confirmed

18:04 - 18:06

**Looking back, what would you have wanted to know about PCa?**

To be confirmed

18:06 - 18:08

**How did you find out about PSA testing?**

To be confirmed

18:08 - 18:10

**Tell us more about your communications with your primary physician**

To be confirmed

18:10 - 18:12

**How should a patient prepare for intake?**

M. Rogan, Galway (IE)

18:12 - 18:16

**Discussion**

18:16 - 18:30

**Early detection**

18:16 - 18:18

**What is PSA testing and why is it so important?**

R.J.A. Van Moorselaar, Amsterdam (NL)

18:18 - 18:20

**Would you consider a PSA test, and if so, why? If not, why?**

M. McRory, Roscommon (IE)

18:20 - 18:22

**Do you know what a digital rectal examination (DRE) is?**

M. McRory, Roscommon (IE)

18:22 - 18:24

**Why is a DRE important?**

R.J.A. Van Moorselaar, Amsterdam (NL)

18:24 - 18:26

**What are the financial consequences of early detection vs. late detection?**

R.J.A. Van Moorselaar, Amsterdam (NL)

18:26 - 18:30

**Discussion**

18:30 - 18:44

**Active surveillance**

18:30 - 18:33

**What is active surveillance and when is it recommended as a treatment option?**

To be confirmed

## Scientific Programme - EAU21 Virtual

---

18:33 - 18:36	<b>Did you have a good understanding of what active surveillance entails?</b> C. Pieri, Milan (IT)
18:36 - 18:39	<b>How did it make you feel when your doctor recommended active surveillance?</b> C. Pieri, Milan (IT)
18:39 - 18:44	<b>Discussion</b>
18:44 - 18:58	<b>Treatment</b>
18:44 - 18:48	<b>What are the most common side-effects of prostate cancer treatment?</b> R. Wassersug, Vancouver (CA)
18:48 - 18:50	<b>What is ADT and when is it recommended as a treatment option?</b> A.S. Merseburger, Lübeck (DE)
18:50 - 18:52	<b>Do you address ADT-related CV risks and other frequent comorbidities with your patients and if so, to what extent?</b> A.S. Merseburger, Lübeck (DE)
18:52 - 18:54	<b>Were you made aware of the cardiovascular risks? Were you made aware of the Pro BNP test, relating to CVD?</b> R. Wassersug, Vancouver (CA)
18:54 - 18:58	<b>Discussion</b>
18:58 - 19:00	<b>Closing remarks</b>

---